Griseofulvin EP Impurity A

Development and validation of a reversed phase liquid chromatographic method for analysis of griseofulvin and impurities
Getu Kahsaya, Aremu Olajire Adegoke b, Ann Van Schepdael a, Erwin Adams
Journal of Pharmaceutical and Biomedical Analysis 80 (2013) 9–17
 
Thermodynamics, Molecular Mobility and Crystallization Kinetics of Amorphous Griseofulvin
Deliang Zhou,Geoff G. Z. Zhang, Devalina Law,David J. W. Grant, and Eric A. Schmitt
Mol. Pharmaceutics 2008, 5, 6, 927–936
 
In Vitro additive effect on griseofulvin and terbinafine combinations against multidrug-resistant dermatophytes
Aline Jacobi Dalla Lana, Bruna Pippi, Anderson Ramos Carvalho, Renata Cougo Moraes, Samuel Kaiser, George Gonzalez Ortega, Alexandre Meneghello Fuentefria, Gustavo Pozza Silveira
Braz. J. Pharm. Sci. vol.54 no.2 São Paulo  2018  Epub July 26, 2018

Griseofulvin EP Impurity A is chemically (1′S,6′R)-7-Chloro-4,6-dimethoxy-6′-methyl-3H-spiro[1-benzofuran-2,1′-cyclohexane]-2′,3,4′-trione, (as per EP). It is also known as Griseofulvic acid . Griseofulvin EP Impurity A is supplied with detailed characterization data compliant with regulatory guideline. Griseofulvin EP Impurity A can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Griseofulvin.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.